Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday. The company’s shares opened today at $19.33.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...
In a report released today, John Hester from Bell Potter maintained a Buy rating on Mesoblast Limited, with a price target of A$4.00. The company’s shares closed today at $1.90.Elevate Your Investing...
In a report released on October 3, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Mesoblast Limited, with a price target of A$3.04. The company’s shares closed last Friday at $1.75.Elevate...
Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...
The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...
The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.